BioNTech's gotistobart receives FDA orphan drug designation, showing promise in improving survival for patients with squamous ...
In July 2025, a class 2 resubmission of tab-cel’s BLA was initiated by Atara Biotherapeutics, developer and sponsor of ...
The dual inhibition of PD-1 and VEGF pathways by ivonescimab aims to enhance immune response and limit tumor angiogenesis, ...
HPV status, particularly combined p16 and HPV positivity, is vital for patient selection in de-escalation strategies for ...
Experts explore evolving treatment strategies for head and neck squamous cell carcinoma, emphasizing biomarker analysis and ...
TROPION-Lung17 will enroll approximately 400 patients across global sites. Participants are randomized 1:1 to receive either Dato-DXd (6.0 mg/kg intravenously every 3 weeks) or docetaxel (75 mg/m² ...
NP-G2-044 (Prilukae), a novel oral fascin inhibitor, has earned orphan drug designation (ODD) from the FDA for the treatment ...
Findings from a phase I trial (NCT04183166) evaluating TG4050, a neoantigen therapeutic vaccine, in patients with operable, ...
The phase 3 IMforte trial(NCT05091567) demonstrated benefit for expanding on maintenance immunotherapy in extensive-stage ...
Physical activity, especially walking, significantly reduces fatigue and improves QOL in nonmetastatic colorectal cancer ...
Novel small molecule inhibitors show promising efficacy in endometrial cancer, with ongoing trials expanding treatment ...
Sevabertinib, targeting HER2 and EGFR mutations, received FDA breakthrough designation for HER2+ NSCLC, showing a 59% overall ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback